iNOS与HIF-1α在骨肉瘤中的表达及其与血管生成的关系  

Relationship of the expression of iNOS and HIF-1α with angiogenesis in osteosarcoma

作　　者：茅文斌[1] 邵增务[1] 

机构地区：[1]同济医科大学协和医院骨科,武汉430022

出　　处：《中国骨肿瘤骨病》2006年第4期210-213,共4页Chinse Journal Of Bone Tumor And Bone Disease

摘　　要：目的探讨诱导型一氧化氮合酶(iNOS)与缺氧诱导因子-1α(HIF-1α)在骨肉瘤组织中的表达,分析两者的相关性,研究两者在骨肉瘤血管形成中所起的作用。方法采用免疫组化S-P法,检测64例骨肉瘤和10例骨软骨瘤、6例骨纤维结构不良中iNOS与HIF-1α蛋白的表达,同时用CD34标记血管内皮细胞,计算微血管密度(MVD)。结果64例骨肉瘤组织中,iNOS的蛋白阳性表达率为70.3%(45/64),与对照组相比差别有非常显著性意义(P<0.01),HIF-1α的阳性表达率为64%(41/64),亦显著高于对照组(P<0.01);iNOS与HIF-1α的表达一致符合率为60.9%(39/64),两者表达显著相关(P<0.05),且与癌组织分期显著相关(P<0.05);MVD平均值为28.6±11.5,iNOS与HIF-1α均阳性的骨肉瘤组织中MVD值高于两者均为阴性者,两者相比较差别有非常显著性意义(P<0.01)。结论骨肉瘤组织中存在iNOS与HIF-1α蛋白的过表达,两者在促进骨肉瘤新生血管生成中具有协同作用,可能在骨肉瘤的发生、发展、转移中起到重要作用。Objective To study the relationship of the expression of Inos and HIF-1a with angiogenesis in osteosarcoma. Methods iNOS and HIF-1a protein expression were detected by immunohistochemical methods in 64 cases of osteosarcoma and 10 cases of osteochondroma and 6 cases of osteofibrous dysplasia and CD34 marking vascular endothelial cell was used to measure the microvascular density （MVD）. Results The posiitive expression rates of iNOS and HIF-1a were 70.3% and 64% in 64 cases of osteosarcoma which showing a significantly difference in the expression of iNOS and HIF-1a between osteosarcoma and control group. The coincidence rate of the expression of iNOS and HIF- 1a was 60.9%（39/ 64） which showing a close relation between them and the expression of iNOS and HIF-1 a were significantly correlated with stage of the tumor. The medium MVD was 28.6± 11.5, much higher in tumor with possitive expression of iNOS and HIF-1a than in tumor with negative expression of them and there was a significantly difference between them. Conclusions There has a overexpression of iNOS and HIF-1a in osteosarcoma and they have a synergistic effect in new angiogenesis of the tumor and it may play an important role in the genesis and development and metastasis of osteosarcoma.

关 键 词：骨肉瘤 诱导型一氧化氮合酶 缺氧诱导因子-1 α 血管生成 

分 类 号：R738.1[医药卫生—肿瘤]